左甲状腺素降低TSH治疗与甲状腺乳头状微小癌主动监测患者rT3升高及fT3稳定相关
本回顾性研究纳入接受主动监测的甲状腺乳头状微小癌且初始甲状腺功能正常的患者,比较左甲状腺素治疗组(TSH低正常组209例、高亚正常组110例)与未治疗对照组的甲状腺激素水平。结果显示治疗组fT4显著升高,fT3无显著差异,fT3/fT4比值降低,rT3及rT3/T3比值显著升高,rT3与fT4正相关。提示LT4治疗可能通过rT3升高缓冲甲状腺激素代谢。
要点
- LT4降低TSH治疗使fT4升高而fT3稳定,rT3及rT3/T3比值升高。
- rT3与fT4正相关(r=0.51,p<0.001),与TSH、fT3、T3无显著相关。
- 主动监测中轻度降低TSH可能伴随甲状腺激素代谢的缓冲机制。
核心结论
- 在甲状腺功能正常的甲状腺乳头状微小癌主动监测患者中,以维持TSH于参考范围下半部分或轻度亚正常范围为目标的LT4治疗与rT3升高及fT3稳定相关。
研究设计与样本
- 回顾性研究,纳入接受主动监测且初始甲状腺功能正常并接受LT4治疗的甲状腺乳头状微小癌患者,按TSH评分分为低正常组(209例)和高亚正常组(110例),并选取年龄性别匹配的未接受LT4治疗的甲状腺功能正常对照。
- 检测TSH、fT4、fT3(电化学发光免疫分析法)及T3、rT3(液相色谱-串联质谱法)。
主要发现
- 与匹配对照相比,低正常组和高亚正常组的fT4水平均显著更高(p<0.001),而fT3水平无显著差异。
- 低正常组和高亚正常组的fT3/fT4比值显著更低,rT3水平及rT3/T3比值显著更高(均p<0.001)。
- 在低正常组和高亚正常组合并分析中,rT3水平与fT4显著正相关(r=0.51,p<0.001),与TSH、fT3或T3无显著相关性。
关键数值与推荐
- TSH分组依据详细TSH评分:低正常组为参考范围下半部分,高亚正常组为轻度亚正常范围。
- rT3与fT4的相关系数r=0.51(p<0.001)。
临床怎么用
- 对于主动监测的甲状腺功能正常甲状腺乳头状微小癌患者,LT4降低TSH治疗时需关注rT3升高及fT4/fT3平衡变化。
- fT3稳定而fT4升高、rT3升高可能反映甲状腺激素代谢的补偿性缓冲,解读甲状腺功能指标时应综合考虑。
局限性
- 回顾性研究设计。
- 样本来自单中心特定人群,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We previously reported that lowering serum thyrotropin (TSH) levels with levothyroxine (LT4) during active surveillance (AS) of papillary thyroid microcarcinoma (PTMC) was associated with a trend toward a lower rate of disease progression. In euthyroid patients with PTMC managed with mild TSH-lowering therapy, free thyroxine (fT4) levels increased, whereas free triiodothyronine (fT3) levels remained unchanged overall, thereby raising questions regarding thyroid hormone metabolism. We therefore investigated thyroid hormone balance, with particular focus on thyroxine (T4) metabolism, including serum reverse triiodothyronine (rT3). METHODS: This retrospective study included patients with PTMC undergoing AS who were initially euthyroid and treated with LT4. At the final follow-up, patients were classified according to the detailed TSH score: 209 in the low normal group (lower half of the reference range) and 110 in the high subnormal group (mildly subnormal range). Age- and sex-matched controls were selected from euthyroid PTMC patients undergoing AS who had not received LT4. TSH, fT4, fT3, triiodothyronine (T3), and rT3 levels were analyzed. TSH, fT4, and fT3 were measured using an electrochemiluminescence immunoassay, and T3 and rT3 were measured using liquid chromatography-tandem mass spectrometry. RESULTS: Compared with matched controls, both the low normal and high subnormal groups showed significantly higher fT4 levels (p < 0.001), while fT3 levels did not differ significantly. The fT3/fT4 ratio was significantly lower, whereas the rT3 levels and the rT3/T3 ratio were significantly higher in both the low normal and high subnormal groups (all p < 0.001). In analyses combining the low normal and high subnormal groups, rT3 levels were significantly and positively correlated with fT4 (r = 0.51, p < 0.001), whereas no significant correlations were observed with TSH, fT3, or T3. CONCLUSIONS: In euthyroid patients with PTMC undergoing AS, LT4 therapy aimed at maintaining TSH within the lower half of the reference range or within the mildly subnormal range was associated with higher rT3 and stable fT3 levels. These findings raise the possibility of a compensatory buffering mechanism in thyroid hormone metabolism.
引用
- Furumura Y, Miyauchi A, Ito M, et al. TSH-Lowering Levothyroxine Therapy Is Associated with Higher rT3 and Stable fT3 Levels in Euthyroid Patients with Papillary Thyroid Microcarcinoma During Active Surveillance. Thyroid. 2026. PMID: 42675828. doi:10.1177/10507256261484710
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。